# Acrivon Therapeutics, Inc. Common Stock (ACRV)

> Acrivon Therapeutics, Inc. Common Stock (ACRV) trades at $1.15 (-17.90%) as of 4:29:53 PM EST on Nov 20, 2026, -32.95% over the past month. Market cap is $60.08M, with 11.4 days to cover in short interest.

Canonical: https://massive.com/quote/acrv
Data as of: 2026-11-20T21:29:53.679Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.15** -0.25 (-17.90%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.22** +0.07 (+6.09%)
As of 4:29:53 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Acrivon Therapeutics, Inc. Common Stock (ACRV) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -15.71% |
| 1W | -18.62% |
| 1M | -32.95% |
| YTD | -51.04% |
| 1Y | -48.70% |
| 52-wk range | $0.97 – $3.56 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for ACRV: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.97 – $1.40 |
| Open | $1.40 |
| Prev close | $1.40 |
| Volume | 1.29M |
| Market cap | $60.08M |
| Shares out | 42.85M |

## Valuation and profitability ratios

Valuation and profitability ratios for Acrivon Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.85 |
| P/FCF | — |
| ROE | -104.4% |
| ROA | -86.2% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 19, 2026

## Insider trading

[Acrivon Therapeutics, Inc. Common Stock (ACRV) insider trading](https://massive.com/quote/acrv/insider-trading.md): open-market Form 4 buys and sells by Acrivon Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Acrivon Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 16, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 16, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2026, and providing business updates.”
- Nov 10, 2026 · Business update
  “The webcast ... \[was\] to discuss Acrivon's new immunology and inflammation (I&I) programs, acquired using its AI-driven AP3 platform, including the ACR-525 and PKCθ inhibitor preclinical programs and initial development plans in EoE.”
- Nov 6, 2026 · Asset purchase or sale
  “As consideration for the transfer of the Acquired Assets, the Company has paid cash, and the Company has no obligation to make additional payments, including milestone or royalty payments, in respect of the Transaction.”
- Jun 17, 2026 · Equity compensation grant
  “The stockholders approved the Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan. Subject to the terms and conditions of the Amended and Restated 2022 Plan, the aggregate number of shares of the Company's common stock that may be issued pursuant to awards granted under the Amended and Restated 2022 Plan is 8,606,723 shares, which includes an increase of 3,000,000 shares approved by the Company's stockholders at the Annual Meeting.”
- Mar 19, 2026 · Investor presentation
  “The Company posted to the "Investors & Media" section of the Company's website at ir.acrivon.com, a corporate presentation providing an update on the Company's business (the "Corporate Presentation").”

## ACRV short interest

How heavily ACRV is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 11.4 |
| Short interest | 1.8M |
| Avg volume | 158.68K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ACRV news

The latest news and headlines about Acrivon Therapeutics, Inc. Common Stock (ACRV).

- [Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB](https://www.globenewswire.com/news-release/2026/11/06/3397471/0/en/acrivon-expands-into-immunology-and-inflammation-with-acquisition-of-phase-2-ready-differentiated-oral-jak1-inhibitor-acr-525-and-pkc%CE%B8-inhibitor-preclinical-program-from-aqilion-ab.html) · GlobeNewswire Inc. · Nov 6, 2026 · positive sentiment
- [Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities](https://www.globenewswire.com/news-release/2026/04/17/3276471/0/en/Acrivon-to-Highlight-Preclinical-Data-with-Three-Posters-at-AACR-Demonstrating-Strong-ACR-368-and-ACR-2316-Synergies-with-Immune-Checkpoint-Inhibitors-and-ADC-Payloads-Revealing-Br.html) · GlobeNewswire Inc. · Apr 17, 2026 · positive sentiment
- [Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors](https://www.globenewswire.com/news-release/2026/03/17/3257773/0/en/Acrivon-Therapeutics-to-Present-Pre-Clinical-AP3-Data-at-the-2026-AACR-Annual-Meeting-Revealing-Strong-Synergy-of-ACR-368-with-ADC-Topo-1-Inhibitor-Payloads-and-of-both-ACR-368-and.html) · GlobeNewswire Inc. · Mar 17, 2026 · positive sentiment
- [Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms \| DelveInsight](https://www.globenewswire.com/news-release/2025/07/15/3115921/0/en/Endometrial-Cancer-Clinical-Trial-Pipeline-Insights-50-Companies-Shaping-Future-Treatment-Paradigms-DelveInsight.html) · GlobeNewswire Inc. · Jul 15, 2025 · positive sentiment
- [Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis](https://www.globenewswire.com/news-release/2024/09/14/2946234/0/en/Acrivon-Therapeutics-Reports-Positive-Endometrial-Cancer-Data-from-Ongoing-ACR-368-Registrational-Intent-Phase-2-Study-at-ESMO-Advancement-of-ACR-2316-into-Clinic-Ahead-of-Timeline.html) · GlobeNewswire Inc. · Sep 14, 2024 · positive sentiment

## About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Listed | Nov 15, 2022 |

[Company website](https://www.acrivon.com)

## FAQ

### What is the Acrivon Therapeutics, Inc. Common Stock (ACRV) stock price today?

Acrivon Therapeutics, Inc. Common Stock (ACRV) is trading at $1.15 (-17.90% on the day) as of 4:29:53 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Acrivon Therapeutics, Inc. Common Stock?

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification…

### What is the short interest in ACRV?

As of Oct 30, 2026, ACRV has 1.8M shares short and 11.4 days to cover.

### What exchange is ACRV listed on?

Acrivon Therapeutics, Inc. Common Stock (ACRV) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ACRV quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ACRV`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Acrivon Therapeutics, Inc. Common Stock (ACRV) insider trading](https://massive.com/quote/acrv/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
